Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Phase II Trial of Hypomethylating Agent Combined with Nivolumab for Acute Myeloid Leukaemia Relapse after Allogeneic Haematopoietic Cell Transplantation-Immune Signature Correlates with Response.

Petya Apostolova,Stefanie Kreutmair,Cristina Toffalori,Marco Punta,Susanne Unger, Ann-Cathrin Burk,Claudia Wehr,Kristina Maas-Bauer,Wolfgang Melchinger,Eileen Haring,Rouven Hoefflin,Khalid Shoumariyeh,Valerie Hupfer,Eliza Maria Lauer,Sandra Duquesne,Theresa Lowinus,Nicolas Gonzalo Nunez,Chiara Alberti, Sara da Costa Pereira,Carla Helena Merten,Laura Power,Matthias Weiss, Caroline Boeke,Dietmar Pfeifer,Reinhard Marks,Hartmut Bertz,Ralph Waesch,Gabriele Ihorst,Bernhard Gentner,Justus Duyster,Melanie Boerries,Geoffroy Andrieux,Juergen Finke,Burkhard Becher,Luca Vago,Robert Zeiser

BRITISH JOURNAL OF HAEMATOLOGY（2023）

Cited 5|Views77
Key words
acute myeloid leukaemia,allogeneic haematopoietic cell transplantation,hypomethylating agent,immune checkpoint inhibition,immune phenotype,relapse,single-cell immunomonitoring,single-cell RNA-sequencing
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined